Antivascular endothelial growth factors for inflammatory chorioretinal disorders

Maurizio Battaglia Parodi, Pierluigi Iacono, Frank D. Verbraak, Francesco Bandello

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Macular edema (ME) and choroidal neovascularization (CNV) can complicate the course of several inflammatory chorioretinal diseases, leading to a severe visual function impairment. The most frequently involved clinical entities include for example multifocal choroiditis, presumed ocular histoplasmosis syndrome, Beçhet's disease, multiple evanescent white dot syndrome, birdshot chorioretinopathy, acute multifocal posterior placoid pigment epitheliopathy, serpiginous choroiditis, and persistent placoid maculopathy. Results that have reported on antivascular endothelial growth factor (anti-VEGF) treatment in uveitic patients with CNV or ME have demonstrated positive results in many cases. However, bearing in mind that it has been proven impossible to perform randomized clinical trials with anti-VEGF in uveitic patients with CNV or ME, further studies with longer follow-ups are necessary to assess the value of this therapeutic approach.

Original languageEnglish
Title of host publicationAnti-VEGF
PublisherS. Karger AG
Pages84-95
Number of pages12
Volume46
ISBN (Print)9783805595308, 9783805595292
DOIs
Publication statusPublished - Aug 13 2010

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Antivascular endothelial growth factors for inflammatory chorioretinal disorders'. Together they form a unique fingerprint.

Cite this